Cargando…
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation carrier-added Lu-177. PRRT has recently been developed...
Autores principales: | Harris, Philip E., Zhernosekov, Konstantin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659917/ https://www.ncbi.nlm.nih.gov/pubmed/36387893 http://dx.doi.org/10.3389/fendo.2022.941832 |
Ejemplares similares
-
Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
por: Opalińska, Marta, et al.
Publicado: (2022) -
Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023) -
New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022) -
PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020) -
What comes next?
por: Naeem, Shahid
Publicado: (2019)